drugset / Trial / NCT00003390

6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer

NCT00003390

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 6-hydroxymethylacylfulvene in treating patients with metastatic kidney cancer.

Timeline

Start
1998-06
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject irofulven Small molecule Intravenous

Indications